Physician profile
Nyla Cooper
NPI 1477071330
$4,986.91
in general payments reported to CMS, 2019-2025
28 companies · $21.84 in 2025
The $21.84 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,107 · 2022: $1,965 · 2023: $812 · 2024: $80.66 · 2025: $21.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $901.68 | 2021-2023 | |
| Lilly USA, LLC | $567.89 | 2021-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $379.36 | 2021-2023 | |
| Dexcom, INC. | $375.22 | 2021-2023 | Dexcom G7 Gss (161) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.82 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $274.65 | 2021-2023 | Farxiga |
| Amgen INC. | $259.43 | 2021-2022 | |
| Novo Nordisk INC | $244.98 | 2021-2024 | |
| Insulet Corporation | $209.20 | 2021-2023 | Omnipod |
| Xeris Pharmaceuticals, INC. | $205.87 | 2021-2023 | Gvoke Hypopen |
| Zealand Pharma US, INC. | $195.85 | 2021-2022 | |
| Esperion Therapeutics, INC. | $143.47 | 2021 | |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Neurocrine Biosciences, INC. | $116.05 | 2023 | Ingrezza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $96.35 | 2021-2023 | Freestyle Libre 2 |
| Ibsa Pharma INC. | $80.67 | 2021-2022 | |
| Mannkind Corporation | $78.49 | 2021-2023 | Afrezza |
| Merck Sharp & Dohme LLC | $50.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $38.29 | 2023 | |
| Becton, Dickinson and Company | $31.47 | 2021 | |
| Grt US Holding, INC. | $24.39 | 2022 | |
| Cequr Corporation | $24.33 | 2021 | |
| Corcept Therapeutics | $22.78 | 2021 | |
| Acadia Pharmaceuticals INC | $21.84 | 2025 | Nuplazid |
| Amryt Pharma Holdings LTD | $16.89 | 2021 | |
| Amarin Pharma, INC. | $15.82 | 2021 | |
| Nestle Healthcare Nutrition INC. | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nyla Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.